• Marieke Pape, VissersPauline A JPAJ0000-0002-0677-888XDepartment of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, the Netherlands.Department of Surgery, Radboud University Medical Centre, Nijmegen, the Netherlands., David Bertwistle, Laura McDonald, Laurens V Beerepoot, Mark I van Berge Henegouwen, Sjoerd M Lagarde, Stella Mook, MohammadNadia HajNHDepartment of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands., Paul M Jeene, van LaarhovenHanneke W MHWMDepartment of Medical Oncology, Cancer Centre Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., and VerhoevenRob H ARHA0000-0001-9678-1611Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, the Netherlands.Department of Medical Oncology, Cancer Centre Amsterdam, Amsterdam UMC, University of Amsterdam, A.
• Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, the Netherlands.
• Br J Surg. 2022 Nov 22; 109 (12): 126412731264-1273.

BackgroundPatients with cancer of the oesophagus or gastro-oesophageal junction have a high risk of recurrence after treatment with curative intent. The aim of this study was to analyse the site of recurrence, treatment, and survival in patients with recurrent disease.MethodsPatients with non-metastatic oesophageal or junctional carcinoma treated with curative intent between January 2015 and December 2016 were selected from the Netherlands Cancer Registry. Data on recurrence were collected in the second half of 2019. Overall survival (OS) was assessed by Kaplan-Meier methods.ResultsIn total, 862 of 1909 patients (45.2 per cent) for whom information on follow-up was available had disease recurrence, and 858 patients were included. Some 161 of 858 patients (18.8 per cent) had locoregional recurrence only, 415 (48.4 per cent) had distant recurrence only, and 282 (32.9 per cent) had combined locoregional and distant recurrence. In all, 518 of 858 patients (60.4 per cent) received best supportive care only and 315 (39.6 per cent) underwent tumour-directed therapy. Patients with locoregional recurrence alone more often received chemoradiotherapy than those with distant or combined locoregional and distant recurrence (19.3 per cent versus 0.7 and 2.8 per cent), and less often received systemic therapy (11.2 per cent versus 30.1 and 35.8 per cent). Median OS was 7.6, 4.2, and 3.3 months for patients with locoregional, distant, and combined locoregional and distant recurrence respectively (P < 0.001).ConclusionDisease recurred after curative treatment in 45.2 per cent of patients. Locoregional recurrence developed in only 18.8 per cent. The vast majority of patients presented with distant or combined locoregional and distant recurrence, and received best supportive care.© The Author(s) 2022. Published by Oxford University Press on behalf of BJS Society Ltd.

20 keywords...

hide…